Vericel (VCEL) Other Non-Current Liabilities (2010 - 2026)
Vericel's (VCEL) quarterly Other Non-Current Liabilities came in at $1.9 million in Q1 2026, up 1.68% year-on-year from $1.8 million in Q1 2025, and down 0.9% quarter-over-quarter from $1.9 million in Q4 2025.
Vericel (VCEL) Other Non-Current Liabilities (2010 - 2026) Analysis & Trends
Vericel has disclosed Other Non-Current Liabilities across 17 years of filings, most recently posting $1.9 million for Q1 2026.
- Other Non-Current Liabilities for Q1 2026 came in at $1.9 million, up 1.68% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.9 million (up 1.68% YoY), and the FY2025 annual result was $1.9 million, up 116.44% from the prior year.
- Other Non-Current Liabilities came in at $1.9 million for Q1 2026 at Vericel, down from $1.9 million in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $1.9 million in Q4 2025 to a low of $19000.0 in Q1 2022.
- The 5-year median for Other Non-Current Liabilities is $220500.0 (2024), against an average of $761142.9.
- Across the five-year window, Other Non-Current Liabilities sank 66.67% in 2022 and soared 1100.0% in 2025, its largest moves.
- Vericel's Other Non-Current Liabilities stood at $21000.0 in 2022, then jumped by 376.19% to $100000.0 in 2023, then soared by 776.0% to $876000.0 in 2024, then soared by 116.44% to $1.9 million in 2025, then decreased by 0.9% to $1.9 million in 2026.
- The last three Other Non-Current Liabilities figures came in at $1.9 million (Q1 2026), $1.9 million (Q4 2025), and $1.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Vericel | 2.04 Bn | 1.90 Bn | 49.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.88 Mn |
| Dec 31, 2025 | 1.90 Mn |
| Sep 30, 2025 | 1.67 Mn |
| Jun 30, 2025 | 1.66 Mn |
| Mar 31, 2025 | 1.85 Mn |
| Dec 31, 2024 | 876,000.00 |
| Sep 30, 2024 | 243,000.00 |
| Jun 30, 2024 | 198,000.00 |
| Mar 31, 2024 | 154,000.00 |
| Dec 31, 2023 | 100,000.00 |
| Sep 30, 2023 | 65,000.00 |
| Jun 30, 2023 | 28,000.00 |
| Jun 30, 2022 | 21,000.00 |
| Mar 31, 2022 | 19,000.00 |
| Dec 31, 2021 | 44,000.00 |
| Sep 30, 2021 | 42,000.00 |
| Jun 30, 2021 | 62,000.00 |
| Mar 31, 2021 | 57,000.00 |
| Dec 31, 2020 | 76,000.00 |
| Sep 30, 2020 | 74,000.00 |